The global Amyotrophic Lateral Sclerosis treatment market is anticipated to grow rapidly owing to rising incidence and prevalence of ALS worldwide. Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neuromuscular disease that attacks nerve cells in the brain and spinal cord causing loss of muscle control. Currently, the only FDA-approved drug for ALS is riluzole which marginally extends lifespan by 2-3 months. The treatment landscape is changing with several pipeline drugs in late stages of development.

The global Amyotrophic Lateral Sclerosis treatment market is estimated to be valued at US$ 692.77 Mn in 2024 and is expected to exhibit a CAGR of 4.6% over the forecast period 2023 to 2030.

Key Takeaways

Key players operating in the Amyotrophic Lateral Sclerosis treatment are Orion Corporation, Bausch Health Companies Inc., CYTOKINETICS, INC., Aquestive Therapeutics, Inc., Sanofi ,Covis Pharma, Sun Pharmaceuticals Industries Ltd, Mitsubishi Tanabe Pharma Corporation, BrainStorm Cell Limited, ViroMed Co., Ltd, Ionis Pharmaceuticals, Genervon Biopharmaceuticals, LLC, Biogen, Orphazyme A/S, Apotex Inc, Neuralstem, Inc., Implicit Bioscience, F. Hoffmann-La Roche Ltd, AB Science, ADVANZ PHARMA.

The ALS treatment market offers significant opportunities with Biogen's investigational drug tofersen providing hope. Tofersen aims to treat aroot cause of ALS by targeting SOD1 gene mutations. Positive phase III data would accelerate approval. Orphazyme’s arimoclomol aims to treat all types of ALS through addressing protein misfolding and aggregation. Positive phase III readout is expected in 2023.

Leading pharma players are expanding globally with their clinical programs and drug candidates. Biogen, Roche and Mitsubishi Tanabe Pharma are expanding clinical trials of their drugs worldwide including in Asia Pacific and European countries. This would aid faster access to treatment for ALS patients globally.

Market Drivers
Rising prevalence of ALS due to aging population worldwide is a key driver. According to the ALS Association, about 5,000 new ALS cases are diagnosed annually in the US alone. Increasing research funding for development of new drugs and diagnostics is another major factor fueling market growth. Robust pipelines with several drugs in phase III would boost the market once approved.

Market Restraints
High cost of ALS treatment poses a major challenge. Currently, there is only one approved drug riluzole available which provides limited benefits. Difficulties associated with clinical trials due to heterogeneity of the disease also impacts drug development. Long approval timelines restrain faster market growth.


Segment Analysis
The ALS treatment market is dominated by the Riluzole segment due to its early FDA approval and popularity as the only approved drug. Riluzole inhibits glutamate release and prolongs survival in some patients. However, it provides only modest benefits and more effective treatment options are needed. Other promising segments include Edaravone and Gene therapy. Edaravone is a free radical scavenger which showed short-term benefits in a phase 3 trial. It is approved in some regions and its usage is increasing. Gene therapy aims to deliver neurotrophic factors or replace deficient genes. While still in clinical trials, it has the potential to slow or halt disease progression if proven safe and effective.

Global Analysis
North America dominates the ALS treatment market due to high awareness, developed healthcare infrastructure and strong presence of leading pharmaceutical companies. The region accounted for over 40% market share in 2024 led by the US. However, Asia Pacific is expected to grow at the fastest pace during the forecast period due to rising healthcare expenditure, large patient pool and increasing focus on rare disease treatment in countries like China, India and Japan. Meanwhile, Europe continues to be the second largest region driven by supportive regulatory environment and government funding for research initiatives.

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement.

(LinkedIn- https://www.linkedin.com/in/priya-pandey-8417a8173/___